Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (Nasdaq: SABS), or SAB BIO, generates frequent news as a clinical-stage biopharmaceutical company advancing fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies for immune and autoimmune disorders. Most recent headlines focus on SAB-142, the company’s multi-specific, fully human anti-thymocyte globulin in development as a potentially disease-modifying, redosable immunotherapy for autoimmune type 1 diabetes (T1D) in new-onset, Stage 3 patients.
News updates commonly cover clinical milestones for SAB-142, including Phase 1 trial results and the launch and progress of the Phase 2b registrational SAFEGUARD study. Releases describe safety, pharmacodynamic, and immunogenicity findings, such as the absence of serum sickness and anti-drug antibodies in the Phase 1 trial, as well as the design and enrollment status of the SAFEGUARD trial at multiple centers around the world.
SABS news also highlights SAB BIO’s scientific presence at major medical meetings. The company regularly announces oral and poster presentations at conferences such as the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the Asian Conference on Innovative Therapies for Diabetes Management. These items detail new data on SAB-142’s mechanism of action, immunomodulatory effects without sustained lymphodepletion, and pharmacokinetic profiling.
Investors and observers will also find corporate and investor-relations updates, including participation in healthcare investor conferences and changes to the Board of Directors, as well as summaries of quarterly financial results and business highlights. For anyone tracking SABS, this news feed provides an ongoing view into SAB BIO’s clinical development progress, scientific communications, governance developments, and key events related to its lead program SAB-142 and its broader human IgG platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.